Mouse Syndecan-1/CD138 Antibody

Syndecan‑1/CD138 in NMuMG Mouse Cell Line.

Syndecan-1/CD138 was detected in immersion fixed NMuMG mouse mammary gland epithelial cell line using Mouse Syndecan-1/CD138 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF3190) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (yellow; Catalog # NL001) and counterstained with DAPI (blue). Specific staining was localized to cell surfaces and cytoplasm. View our protocol for Fluorescent ICC Staining of Cells on Coverslips.

Syndecan‑1/CD138 in Mouse Kidney.

Syndecan-1/CD138 was detected in perfusion fixed frozen sections of mouse kidney using Goat Anti-Mouse Syndecan-1/CD138 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF3190) at 3 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Goat IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC004). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to glomeruli and convoluted tubules. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents.

Detection of Syndecan-1 by Immunocytochemistry/ Immunofluorescence

Chemotherapy inhibits cytotoxic T lymphocyte activity. A) Gene set enrichment analysis (GSEA) of public RNA‐seq datasets (GSE161801 (n = 30) and GSE223060 (n = 41)) of the immune‐response‐gene‐related signatures between newly diagnosed patients, undergoing treatment and those in relapse. NES, normalized enrichment score. B) Representative two patient's UMAP plot of the expression of CD3D, CD8, CD69, and IFNG in a public scRNA‐seq data (GSE161801) (n = 30). UMAP: uniform manifold approximation and projection. C,D) Pathway enrichment analysis of public RNA‐seq datasets of the myeloma cells treated with or without melphalan (GSE178292) or bortezomib (GSE171837). E) Immunofluorescent staining of healthy and myeloma patients bone marrow samples before or after chemotherapy with 4',6‐diamidino‐2‐phenylindole dihydrochloride (DAPI) and antibodies against CD138 (myeloma cell marker) or granzyme B (GZB, activity of T cell) (n = 5). Scale bar, 10 µm. F) Box plots showing the relative mean fluorescence intensity (MFI) of CD138 (left panel) or granzyme B (right panel) in the biopsy segment (n = 5). G) The relative expression of TIM3, TOX, TIGIT, PD‐1, or LAG3 in CD8+ T cells isolated from the bone marrow aspirates of another 20 myeloma patients before or after chemotherapy. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/40135791), licensed under a CC-BY license. Not internally tested by R&D Systems.